GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Balaxi Pharmaceuticals Ltd (NSE:BALAXI) » Definitions » Change In Receivables

Balaxi Pharmaceuticals (NSE:BALAXI) Change In Receivables : ₹0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Balaxi Pharmaceuticals Change In Receivables?

Balaxi Pharmaceuticals's change in receivables for the quarter that ended in Dec. 2024 was ₹0 Mil. It means Balaxi Pharmaceuticals's Accounts Receivable stayed the same from Sep. 2024 to Dec. 2024 .

Balaxi Pharmaceuticals's change in receivables for the fiscal year that ended in Mar. 2024 was ₹-65 Mil. It means Balaxi Pharmaceuticals's Accounts Receivable increased by ₹65 Mil from Mar. 2023 to Mar. 2024 .

Balaxi Pharmaceuticals's Accounts Receivable for the quarter that ended in Dec. 2024 was ₹0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Balaxi Pharmaceuticals's Days Sales Outstanding for the three months ended in Dec. 2024 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Balaxi Pharmaceuticals's liquidation value for the three months ended in Dec. 2024 was ₹0 Mil.


Balaxi Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Balaxi Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Balaxi Pharmaceuticals Change In Receivables Chart

Balaxi Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -248.44 -461.67 465.12 -250.51 -64.88

Balaxi Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Balaxi Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Balaxi Pharmaceuticals  (NSE:BALAXI) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Balaxi Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/732.913*91
=0.00

2. In Ben Graham's calculation of liquidation value, Balaxi Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Balaxi Pharmaceuticals's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0-0+0.75 * 0+0.5 * 0
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Balaxi Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Balaxi Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Balaxi Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Phase-III, Road No: 81, Jubilee Hills, Plot No.409, H,No: 8-2-293, MAPS Towers, 3rd Floor, Hyderabad, TG, IND, 500 096
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. Geographically it earns key revenue from Guatemala.

Balaxi Pharmaceuticals Headlines

No Headlines